Clinical Trial News and Research

RSS

ACR releases two new provisional definitions of rheumatoid arthritis remission

The American College of Rheumatology today announced the release of two new provisional definitions of rheumatoid arthritis remission, which are to be applied to future RA clinical trials.

4 Feb 2011

Scientists unravel mystery about how new tumors in individuals with breast cancer take root

In a discovery that may lead to a new treatment for breast cancer that has spread to the bone, a Princeton University research team has unraveled a mystery about how these tumors take root.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

New device to treat heart hiccups

"It took off to about 160 beats per minute and then dropped to 50. It seemed confused. Then it went back to normal," recalled Tsuji, 47, an avid cyclist, of that day in 2003. "I didn't notice any symptoms at that point, so I blew it off. I figured there was something wrong with it."

3 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.

3 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

New study: Clinical trials exclude older patients due to age-related conditions

Older individuals, who constitute a rapidly growing population in the United States, account for a disproportionate share of health care utilization and cost. Yet more than half of clinical trials exclude people based on their age or age-related conditions, according to a new study by Robert Wood Johnson Foundation Clinical Scholars- at the University of Michigan.

2 Feb 2011

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

$Researchers find breast cancer therapy contributes to early-in-life hip fractures in women$

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

A hip fracture is not common in a 54-year-old woman, unless she is a 54-year-old breast cancer survivor, according to a new Northwestern Medicine study. Researchers found that a combination of early menopause due to breast cancer treatment and common drugs used to treat breast cancer, could be weakening the bones of breast cancer survivors once they hit middle age, leading to hip fractures.

2 Feb 2011

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.

2 Feb 2011

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

Cyberonics, Inc. today announced that the AspireHC™ (High Capacity) generator for use in vagus nerve stimulation (VNS) therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.

2 Feb 2011

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

BioMarin Pharmaceutical announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome.

1 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Clinical Trial News and Research

ACR releases two new provisional definitions of rheumatoid arthritis remission

Scientists unravel mystery about how new tumors in individuals with breast cancer take root

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

AVEO receives USAN, WHO generic name approval for ficlatuzumab

New device to treat heart hiccups

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

First therapeutic vaccine designed from dendritic cells of patient achieves significant response

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

New study: Clinical trials exclude older patients due to age-related conditions

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

FDA approves Cyberonics Aspire High Capacity generator for vagus nerve stimulation therapy

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News